Information on acute overdosage with Pletal (cilostazol) in humans is limited. The signs and symptoms of an acute overdose can be anticipated to be those of excessive pharmacologic effect: severe headache, diarrhea, hypotension, tachycardia, and possibly cardiac arrhythmias. The patient should be carefully observed and given supportive treatment. Since cilostazol is highly protein-bound, it is unlikely that it can be efficiently removed by hemodialysis or peritoneal dialysis. The oral LD₅₀ of cilostazol is > 5.0 g/kg in mice and rats and > 2.0 g/kg in dogs.

Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV congestive heart failure. Pletal (cilostazol) is contraindicated in patients with congestive heart failure of any severity.

Pletal (cilostazol) is contraindicated in patients with haemostatic disorders or active pathologic bleeding, such as bleeding peptic ulcer and intracranial bleeding. Pletal (cilostazol) inhibits platelet aggregation in a reversible manner.

Pletal (cilostazol) is contraindicated in patients with known or suspected hypersensitivity to any of its components.

Last reviewed on RxList: 12/19/2007
This monograph has been modified to include the generic and brand name in many instances.